Cognitive impact of anticholinergic medication in MS: Adding insult to injury?

Multiple Sclerosis and Related Disorders

Volumn 1, Issue 4, 2012, Pages 156-161

  Cruce, Roxana ^a,b   Vosoughi, Reza ^a,b,c   Freedman, Mark S ^a,b  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

^c UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Anticholinergic therapy; Bladder symptoms; Cognition; Drug side effect; Multiple Sclerosis; Symptomatic therapy

Indexed keywords

CHOLINERGIC RECEPTOR BLOCKING AGENT; VIRUS PROTEIN;

ADULT; ARTICLE; BECK DEPRESSION INVENTORY; BLADDER DYSFUNCTION; CLINICAL ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DEPRESSION; DISEASE ASSOCIATION; DRUG EFFECT; DRUG SAFETY; FATIGUE; FEMALE; HUMAN; MALE; MENTAL FUNCTION; MENTAL PERFORMANCE; MODIFIED FATIGUE IMPACT SCALE; MULTIPLE SCLEROSIS; PSYCHOLOGIC TEST; SELECTIVE REMINDING TEST; SYMBOL DIGIT MODALITY TEST; TREATMENT DURATION;

EID: 84865259849     PISSN: 22110348     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.msard.2012.05.002     Document Type: Article

References (75)

1. P. Abrams, K.E. Andersson, J.J. Buccafusco, C. Chapple, W.C. de Groat, and A.D. Fryer Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder British Journal of Pharmacology 148 5 2006 565 578
2. A. Achiron, M. Polliack, S.M. Rao, Y. Barak, M. Lavie, and N. Appelboim Cognitive patterns and progression in multiple sclerosis: construction and validation of percentile curves Journal of Neurology, Neurosurgery, and Psychiatry 76 5 2005 744 749
3. M.P. Amato, V. Zipoli, and E. Portaccio Multiple sclerosis-related cognitive changes: a review of cross-sectional and longitudinal studies Journal of the Neurological Sciences 15; 245 12 2006 41 46
4. M.P. Amato, E. Portaccio, B. Goretti, V. Zipoli, L. Ricchiuti, and M.F. De Caro The Raos Brief Repeatable Battery and Stroop Test: normative values with age, education and gender corrections in an Italian population Multiple Sclerosis 12 6 2006 787 793
5. M.P. Amato, E. Portaccio, B. Goretti, V. Zipoli, B. Hakiki, and M. Giannini Cognitive impairment in early stages of multiple sclerosis Neurological Sciences 31 Suppl 2 2010 S211 S214
6. M.P. Amato, E. Portaccio, B. Goretti, V. Zipoli, A. Iudice, and D. Della Pina Relevance of cognitive deterioration in early relapsing-remitting MS: a 3-year follow-up study Multiple Sclerosis 16 12 2010 1474 1482
7. M.L. Ancelin, S. Artero, F. Portet, A.M. Dupuy, J. Touchon, and K. Ritchie Non-degenerative mild cognitive impairment in elderly people and use of anticholinergic drugs: longitudinal cohort study British Medical Journal 332 7539 2006 455 459
8. A.K. Andreasen, P.E. Spliid, H. Andersen, and J. Jakobsen Fatigue and processing speed are related in multiple sclerosis European Journal of Neurology 17 2 2010 212 218
9. S. Artero, M.L. Ancelin, F. Portet, A. Dupuy, C. Berr, and J.F. Dartigues Risk profiles for mild cognitive impairment and progression to dementia are gender specific Journal of Neurology, Neurosurgery, and Psychiatry 79 9 2008 979 984
10. B. Audoin, M.V. Au Duong, J.P. Ranjeva, D. Ibarrola, I. Malikova, and S. Confort-Gouny Magnetic resonance study of the influence of tissue damage and cortical reorganization on PASAT performance at the earliest stage of multiple sclerosis Human Brain Mapping 24 3 2005 216 228
11. B. Audoin, F. Reuter, M.V. Duong, I. Malikova, S. Confort-Gouny, and A.A. Cherif Efficiency of cognitive control recruitment in the very early stage of multiple sclerosis: a one-year fMRI follow-up study Multiple Sclerosis 14 6 2008 786 792
12. W.W. Beatty, and R.L. Aupperle Sex differences in cognitive impairment in multiple sclerosis Clinical neuropsychology 16 2000 472 480
13. A. Beck, R.A. Steer, and G.K. Brown BDI-Fast Screen for Medical Patients 2000 The Psychological Corporation San Antonio, TX
14. R.H. Benedict, I. Fishman, M.M. McClellan, R. Bakshi, and B. Weinstock-Guttman Validity of the Beck Depression Inventory-Fast Screen in multiple sclerosis Multiple Sclerosis 9 4 2003 393 396
15. R.H. Benedict, E. Wahlig, R. Bakshi, I. Fishman, F. Munschauer, R. Zivadinov, and B. Weinstock-Guttman Predicting quality of life in multiple sclerosis: accounting for physical disability, fatigue, cognition, mood disorder, personality, and behavior change Journal of the Neurological Sciences 231 2005 29 34
16. R.H. Benedict, and R. Zivadinov Risk factors for and management of cognitive dysfunction in multiple sclerosis Nature Reviews Neurology 10; 7 6 2011 332 342
17. J.B. Boringa, R.H. Lazeron, I.E. Reuling, H.J. Adr, L. Pfennings, and J. Lindeboom The brief repeatable battery of neuropsychological tests: normative values allow application in multiple sclerosis clinical practice Multiple Sclerosis 7 4 2001 263 267
18. K.A. Bottiggi, J.C. Salazar, L. Yu, A.M. Caban-Holt, M. Ryan, M.S. Mendiondo, and F.A. Schmitt Long-term cognitive impact of anticholinergic medications in older adults American Journal of Geriatric Psych 14 11 2006 980 984
19. H. Buschke, and P.A. Fuld Evaluating storage, retention, and retrieval in disordered memory and learning Neurology 24 11 1974 1019 1025
20. S. Cader, J. Palace, and P.M. Matthews Cholinergic agonism alters cognitive processing and enhances brain functional connectivity in patients with multiple sclerosis Journal of Psychopharmacology 23 6 2009 686 696
21. M. Calabrese, F. Rinaldi, P. Grossi, I. Mattisi, V. Bernardi, and A. Favaretto Basal ganglia and frontal/parietal cortical atrophy is associated with fatigue in relapsing-remitting multiple sclerosis Multiple Sclerosis 16 10 2010 1220 1228
22. R.M. Carnahan, B.C. Lund, P.J. Perry, B.G. Pollock, and K.R. Culp The Anticholinergic Drug Scale as a measure of drug-related anticholinergic burden: associations with serum anticholinergic activity Journal of Clinical Pharmacology 46 12 2006 1481 1486
23. I. Carrire, A. Fourrier-Reglat, J.F. Dartigues, O. Rouaud, F. Pasquier, K. Ritchie, and ML. Ancelin Drugs with anticholinergic properties, cognitive decline, and dementia in an elderly general population: the 3-city study Archives of Internal Medicine 169 14 2009 1317 1324
24. R. Cutajar, E. Ferriani, C. Scandellari, L. Sabattini, C. Trocino, L.P. Marchello, and S Stecchi Cognitive function and quality of life in multiple sclerosis patients Journal For Neurovirology 6 suppl 2 2000 S186 S190
25. M.S. Deloire, M.C. Bonnet, E. Salort, Y. Arimone, M. Boudineau, and K.G. Petry How to detect cognitive dysfunction at early stages of multiple sclerosis? Multiple Sclerosis 12 4 2006 445 452
26. M. Deloire, A. Ruet, D. Hamel, M. Bonnet, and B. Brochet Early cognitive impairment in multiple sclerosis predicts disability outcome several years later Multiple Sclerosis 16 5 2010 581 587
27. K. Diefenbach, F. Donath, A. Maurer, S. Quispe Bravo, K.D. Wernecke, and U. Schwantes Randomised, double-blind study of the effects of oxybutynin, tolterodine, trospium chloride and placebo on sleep in healthy young volunteers Clinical Drug Investigation 23 6 2003 395 404
28. V.L. DOrio, F.W. Foley, F. Armentano, M.A. Picone, S. Kim, and R. Holtzer Cognitive and motor functioning in patients with multiple sclerosis: neuropsychological predictors of walking speed and falls Journal of the Neurological Sciences 316 1-2 2012 42 46
29. B. Duque, J. Sepulcre, B. Bejarano, L. Samaranch, P. Pastor, and P. Villoslada Memory decline evolves independently of disease activity in MS Multiple Sclerosis 14 7 2008 947 953
30. J.R. Ellis, K.A. Ellis, C.F. Bartholomeusz, B.J. Harrison, K.A. Wesnes, and F.F. Erskine Muscarinic and nicotinic receptors synergistically modulate working memory and attention in humans International Journal of Neuropsychopharmacology 9 2 2006 175 189
31. L. Feuillet, F. Reuter, B. Audoin, I. Malikova, K. Barrau, A.A. Cherif, and J Pelletier Early cognitive impairment in patients with clinically isolated syndrome suggestive of multiple sclerosis Multiple Sclerosis 13 1 2007 124 127
32. J.D. Fisk, Pontefract, P.G. Ritvo, C.J. Archibald, and T.J. Murray The impact of fatigue on patients with multiple sclerosis Canadian Journal of Neurological Sciences 21 1994 9 14
33. C. Fox, K. Richardson, I.D. Maidment, G.M. Savva, F.E. Matthews, and D. Smithard Anticholinergic medication use and cognitive impairment in the older population: the Medical Research Council cognitive function and ageing study Journal of the American Geriatrics Society 59 8 2011 1477 1483
34. K.M. Giramonti, B.A. Kogan, and L.F. Halpern The effects of anticholinergic drugs on attention span and short-term memory skills in children Neurourol Urodyn 27 4 2008 315 318
35. B.I. Glanz, B.C. Healy, L.E. Hviid, T. Chitnis, and H.L. Weiner Cognitive deterioration in patients with early multiple sclerosis: a 5-year study Journal of Neurology, Neurosurgery, and Psychiatry 83 1 2012 38 43
36. K. Glavind, and M Chancellor Antimuscarinics for the treatment of overactive bladder: understanding the role of muscarinic subtype selectivity International Urogynecology Journal 22 8 2011 907 917
37. L. Han, J.V. Agostini, and H.G. Allore Cumulative anticholinergic exposure is associated with poor memory and executive function in older men Journal of the American Geriatrics Society 56 12 2008 2203 2210
38. R. Holtzer, and F. Foley The relationship between subjective reports of fatigue and executive control in multiple sclerosis Journal of the Neurological Sciences 15; 281 12 2009 46 50
39. K. Honarmand, N. Akbar, N. Kou, and A. Feinstein Predicting employment status in multiple sclerosis patients: the utility of the MS functional composite Journal of Neurology 258 2 2011 244 249
40. M. Hoogs, S. Kaur, A. Smerbeck, B. Weinstock-Guttman, and R.H. Benedict Cognition and physical disability in predicting health-related quality of life in multiple sclerosis International Journal of MS Care 13 2 2011 57 63
41. S. Huolman, P. Hmlinen, V. Vorobyev, J. Ruutiainen, R. Parkkola, T. Laine, and H. Hmlinen The effects of rivastigmine on processing speed and brain activation in patients with multiple sclerosis and subjective cognitive fatigue Multiple Sclerosis 17 11 2011 1351 1361
42. S.M. Jakobsen, H. Kersten, and E. Molden Evaluation of brain anticholinergic activities of urinary spasmolytic drugs using a high-throughput radio receptor bioassay Journal of the American Geriatrics Society 59 3 2011 501 505
43. J.H. Kalmar, E.A. Gaudino, N.B. Moore, J. Halper, and J. Deluca The relationship between cognitive deficits and everyday functional activities in multiple sclerosis Neuropsychology 22 4 2008 442 449
44. V. Kalsi, G. Gonzales, R. Popat, A. Apostolidis, S. Elneil, P. Dasgupta, and C.J. Fowler Botulinum injections for the treatment of bladder symptoms of multiple sclerosis Annals of Neurology 62 5 2007 452 457
45. G. Kay, K. Kardiasmenos, and T. Crook Differential effects of the antimuscarinic agents tolterodine tartrate ER and oxybutynin chloride ER on recent memory in older subjects Neurourol Urodyn 25 2006 615
46. S. Khan, X. Game, V. Kalsi, G. Gonzales, J. Panicker, and S. Elneil Long-term effect on quality of life of repeat detrusor injections of botulinum neurotoxinA for detrusor overactivity in patients with multiple sclerosis Journal of Urology 185 4 2011 1344 1349
47. E.J. Kooi, M. Prins, N. Bajic, J.A. Belin, W.H. Gerritsen, and J. van Horssen Cholinergic imbalance in the multiple sclerosis hippocampus Acta Neuropathologica 122 3 2011 313 322
48. L.B. Krupp, C. Christodoulou, P. Melville, W.F. Scherl, W.S. MacAllister, and L.E. Elkins Donepezil improved memory in multiple sclerosis in a randomized clinical trial Neurology 63 9 2004 1579 1585
49. L.B. Krupp, C. Christodoulou, P. Melville, W.F. Scherl, L.Y. Pai, and L.R. Muenz Multicenter randomized clinical trial of donepezil for memory impairment in multiple sclerosis Neurology 76 17 2011 1500 1507
50. D.W. Langdon Cognition in multiple sclerosis Current Opinion in Neurology 24 3 2011 244 249
51. U. Mehnert, J. Birzele, K. Reuter, and B. Schurch The effect of botulinum toxin type a on overactive bladder symptoms in patients with multiple sclerosis: a pilot study Journal of Urology 184 3 2010 1011 1016
52. R.J. Mills, C.A. Young, J.F. Pallant, and A. Tennant Rasch analysis of the modified fatigue impact scale (MFIS) in multiple sclerosis Journal of Neurology, Neurosurgery, and Psychiatry 81 9 2010 1049 1051
53. S.A. Morrow, B. Weinstock-Guttman, F.E. Munschauer, D. Hojnacki, and R.H. Benedict Subjective fatigue is not associated with cognitive impairment in multiple sclerosis: cross-sectional and longitudinal analysis Multiple Sclerosis 15 8 2009 998 1005
54. S.A. Morrow, A. Drake, R. Zivadinov, F. Munschauer, B. Weinstock-Guttman, and R.H. Benedict Predicting loss of employment over three years in multiple sclerosis: clinically meaningful cognitive decline Clinical neuropsychology 24 7 2010 1131 1145
55. G. Nagels, P.P. De Deyn, L. Vleugels, M.B. Dhooghe, I. Van Glabeke, K. Van Laere, and D. De Ridder A prospective randomised double-blind cross-over dose-titration study to evaluate the cognitive safety profile of tolterodine as compared to oxybutynin in multiple sclerosis patients with a neurogenic overactive bladder: a planned interim analysis Multiple Sclerosis 10 2004 150
56. U. Nocentini, P. Pasqualetti, S. Bonavita, M. Buccafusca, M.F. De Caro, and D. Farina Cognitive dysfunction in patients with relapsing-remitting multiple sclerosis Multiple Sclerosis 12 1 2006 77 87
57. B.S. Oken, K. Flegal, D. Zajdel, S.S. Kishiyama, J. Lovera, B. Bagert, and DN. Bourdette Cognition and fatigue in multiple sclerosis: potential effects of medications with central nervous system activity Journal of Rehabilitation Research and Development 43 1 2006 83 90
58. A.M. Parry, R.B. Scott, J Palace, S Smith, and PM Matthews Potentially adaptive functional changes in cognitive processing for patients with multiple sclerosis and their acute modulation by rivastigmine Brain 126 Pt 12 2003 2750 2760
59. B.A. Parmenter, B. Weinstock-Guttman, N. Garg, F. Munschauer, and R.H. Benedict Screening for cognitive impairment in multiple sclerosis using the Symbol Digit Modalities Test Multiple Sclerosis 13 1 2007 52 57
60. C.H. Polman, S.C. Reingold, G. Edan, M. Filippi, H.P. Hartung, and L. Kappos Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria" Annals of Neurology 58 6 2005 840 846
61. E. Portaccio, B. Goretti, V. Zipoli, G. Siracusa, S. Sorbi, and M.P. Amato A short version of Raos Brief Repeatable Battery as a screening tool for cognitive impairment in multiple sclerosis Clinical neuropsychology 23 2 2009 268 275
62. C. Potagas, E. Giogkaraki, G. Koutsis, D. Mandellos, E. Tsirempolou, C. Sfagos, and D. Vassilopoulos Cognitive impairment in different MS subtypes and clinically isolated syndromes Journal of the Neurological Sciences 267 12 2008 100 106
63. S.M. Rao, and Cognitive Function Study Group of the National Multiple Sclerosis Society A Manual for the Brief Repeatable Battery of Neuropsychological Tests in Multiple Sclerosis 1990 National Multiple Sclerosis Society New York
64. S.M. Rao, G.J. Leo, L. Bernardin, and F. Unverzagt Cognitive dysfunction in multiple sclerosis I: Frequency, patterns, and prediction Neurology 41 1991 685 691
65. S. Salvatore, M. Serati, L. Cardozo, S. Uccella, and P. Bolis Cognitive dysfunction with tolterodine use American Journal of Obstetrics and Gynecology 197 2 2007 e8
66. G. Savettieri, D. Messina, V. Andreoli, S. Bonavita, C. Caltagirone, and R. Cittadella Gender-related effect of clinical and genetic variables on the cognitive impairment in multiple sclerosis Journal of Neurology 251 10 2004 1208 1214
67. W.F. Scherl, L.B. Krupp, C. Christodoulou, T.M. Morgan, L. Hyman, and B. Chandler Normative data for the selective reminding test: a random digit dialing sample Psychology Report 95 2 2004 593 603
68. M.M. Schoonheim, H.E. Hulst, D. Landi, O. Ciccarelli, S.D. Roosendaal, and E.J. Sanz-Arigita Gender-related differences in functional connectivity in multiple sclerosis Multiple Sclerosis 18 2 2012 164 173
69. D. Schulz, B. Kopp, A. Kunkel, and J.H. Faiss Cognition in the early stage of multiple sclerosis Journal of Neurology 253 8 2006 1002 1010
70. A. Todorova, B. Vonderheid-Guth, and W. Dimpfel Effects of tolterodine, trospium chloride, and oxybutynin on the central nervous system Journal of Clinical Pharmacology 41 2001 636 644
71. J.W. Tsao, and K.M. Heilman Transient memory impairment and hallucinations associated with tolterodine use New England Journal of Medicine 349 23 2003 2274 2275
72. J.R. Virta, S. Laatu, R. Parkkola, V. Oikonen, J.O. Rinne, and J. Ruutiainen Cerebral acetylcholinesterase activity is not decreased in MS patients with cognitive impairment Multiple Sclerosis 17 8 2011 931 938
73. J.A. Wilken, C. Sullivan, M. Wallin, C. Rogers, R.L. Kane, and H. Rossman Treatment of multiple sclerosis-related cognitive problems with adjunctive modafinil International Journal of MS Care 10 2008 1 10
74. S.G. Williams, and J. Staudenmeier Hallucinations with tolterodine Psychiatric Services 55 11 2004 1318 1319
75. K.B. Womack, and K.M. Heilman Tolterodine and memory: dry but forgetful Archives of Neurology 60 5 2003 771 773